Bellerophon Therapeutics Inc - ESG Rating & Company Profile powered by AI
This Sustainability rating for Bellerophon Therapeutics Inc indicates its reporting of the UN SDGs. The assessment of Bellerophon Therapeutics Inc is assembled by All Street Sevva using proprietary artificial intelligence. Comprehensive ESG analysis of Bellerophon Therapeutics Inc can be accessed by signing up for free.
Bellerophon Therapeutics Inc in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 0.0 and governance score of 8.0.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
81 | Foundation Medicine Inc | 4.1 | High |
81 | PAREXEL International Corp | 4.1 | High |
83 | Bellerophon Therapeutics Inc | 4.0 | High |
83 | BTC Health Ltd | 4.0 | High |
83 | Ad Me Tech Co Ltd | 4.0 | High |
... | ... | ... | |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Bellerophon Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Bellerophon Therapeutics Inc disclose current and historical energy intensity?
Does Bellerophon Therapeutics Inc report the average age of the workforce?
Does Bellerophon Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Bellerophon Therapeutics Inc disclose its ethnicity pay gap?
Does Bellerophon Therapeutics Inc disclose cybersecurity risks?
Does Bellerophon Therapeutics Inc offer flexible work?
Does Bellerophon Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Bellerophon Therapeutics Inc disclose the number of employees in R&D functions?
Does Bellerophon Therapeutics Inc conduct supply chain audits?
Does Bellerophon Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Bellerophon Therapeutics Inc conduct 360 degree staff reviews?
Does Bellerophon Therapeutics Inc disclose the individual responsible for D&I?
Does Bellerophon Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Bellerophon Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Bellerophon Therapeutics Inc disclose water use targets?
Does Bellerophon Therapeutics Inc have careers partnerships with academic institutions?
Did Bellerophon Therapeutics Inc have a product recall in the last two years?
Does Bellerophon Therapeutics Inc disclose incidents of discrimination?
Does Bellerophon Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Bellerophon Therapeutics Inc issued a profit warning in the past 24 months?
Does Bellerophon Therapeutics Inc disclose parental leave metrics?
Does Bellerophon Therapeutics Inc disclose climate scenario or pathway analysis?
Does Bellerophon Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Bellerophon Therapeutics Inc disclose the pay ratio of women to men?
Does Bellerophon Therapeutics Inc support suppliers with sustainability related research and development?
Does Bellerophon Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Bellerophon Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Bellerophon Therapeutics Inc involved in embryonic stem cell research?
Does Bellerophon Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Bellerophon Therapeutics Inc disclose its waste policy?
Does Bellerophon Therapeutics Inc report according to TCFD requirements?
Does Bellerophon Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Bellerophon Therapeutics Inc disclose energy use targets?
Does Bellerophon Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Bellerophon Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Bellerophon Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.